مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

380
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

219
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

THE EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON PREVENTION OF ANEMIA OF PREMATURITY

Pages

  257-262

Abstract

 Objective: Premature infants often develop significant ANEMIA that requires blood transfusion, this carries significant risks. This study was carried out to determine the effect of recombinant human ERYTHROPOIETIN (r-HuEPO) on prevention of ANEMIA of PREMATURITY.
Material & Methods: From April 2001 to March 2002, 24 NEONATEs in newborn services at Amirkola children's hospital randomly were assigned to ERYTHROPOIETIN group and control (no treatment) group. Inclusion criteria were birth weight of  £1750 grams and gestational age £34 weeks. Exclusion criteria were problems of hemolytic ANEMIA, congenital infections, congenital malformations, severe asphyxia, intraventricular hemorrhage (grade III and IV), need for exchange transfusion and death during the first week of life. ERYTHROPOIETIN group received r-HuEPO400 unit/kg/dose subcutaneously three times a week plus 4 mg/kg/day iron orally. White blood cell, hemoglobin (Hgb), hematocrit (Hct), platelet and reticulocyte count were obtained every 2 weeks until the 42nd day of life. ANEMIA was defined as Hgb£8gr/dl and Hct£24%. Student t test and Fisher exact were used to evaluate differences between the two groups.
Findings: Hemoglobin and hematocrit values were significantly higher in ERYTHROPOIETIN group than the control group after the 14th day of the study (P<0.04) and this difference was getting higher until the end of the trial (P<0.001). Five NEONATEs developed ANEMIA; all of them were from control group. One of these NEONATEs required transfusion. None of the ERYTHROPOIETIN group newborns developed ANEMIA.
Conclusion: The results of this study confirm the efficacy of recombinant human ERYTHROPOIETIN in the prevention of ANEMIA of PREMATURITY.

Multimedia

  • No record.

    • Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    AHMADPOUR KACHOU, M., ZAHED PASHA, Y.A., HAJIAN, K., & MORADI, SH.. (2007). THE EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON PREVENTION OF ANEMIA OF PREMATURITY. IRANIAN JOURNAL OF PEDIATRICS, 17(3), 257-262. SID. https://sid.ir/paper/558158/en

    Vancouver: Copy

    AHMADPOUR KACHOU M., ZAHED PASHA Y.A., HAJIAN K., MORADI SH.. THE EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON PREVENTION OF ANEMIA OF PREMATURITY. IRANIAN JOURNAL OF PEDIATRICS[Internet]. 2007;17(3):257-262. Available from: https://sid.ir/paper/558158/en

    IEEE: Copy

    M. AHMADPOUR KACHOU, Y.A. ZAHED PASHA, K. HAJIAN, and SH. MORADI, “THE EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON PREVENTION OF ANEMIA OF PREMATURITY,” IRANIAN JOURNAL OF PEDIATRICS, vol. 17, no. 3, pp. 257–262, 2007, [Online]. Available: https://sid.ir/paper/558158/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button